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Abstract
Background: Brain morphometric abnormalities in schizophrenia have been extensively reported in the literature.
Whole-brain volumetric reductions are almost universally reported by most studies irrespective of the characteristics
of the samples studied (e.g., chronic/recent-onset; medicated/neuroleptic-naïve etc.). However, the same cannot be
said of the reported regional morphometric abnormalities in schizophrenia. While certain regional morphometric
abnormalities are more frequently reported than others, there are no such abnormalities that are universally reported
across studies. Variability of socio-demographic and clinical characteristics across study samples as well as technical and
methodological issues related to acquisition and analyses of brain structural images may contribute to inconsistency of
brain morphometric findings in schizophrenia. The objective of the present study therefore was to systematically
examine brain morphometry in patients with recent-onset schizophrenia to find out if there are significant whole-brain
or regional volumetric differences detectable at the appropriate significance threshold, after attempting to control for
various confounding factors that could impact brain volumes.
Methods: Structural magnetic resonance images of 90 subjects (schizophrenia = 45; healthy subjects = 45) were
acquired using a 3 Tesla magnet. Morphometric analyses were carried out following standard analyses pipelines
of three most commonly used strategies, viz., whole-brain voxel-based morphometry, whole-brain surface-based
morphometry, and between-group comparisons of regional volumes generated by automated segmentation and
parcellation.
Results: In our sample of patients having recent-onset schizophrenia with limited neuroleptic exposure, there
were no significant whole brain or regional brain morphometric abnormalities noted at the appropriate statistical
significance thresholds with or without including age, gender and intracranial volume or total brain volume in
the statistical analyses.
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Conclusions: In the background of the conflicting findings in the literature, our findings indicate that brain
morphometric abnormalities may not be directly related to the schizophrenia phenotype. Analysis of the reasons
for the inconsistent results across studies as well as consideration of alternate sources of variability of brain
morphology in schizophrenia such as epistatic and epigenetic mechanisms could perhaps advance our
understanding of structural brain alterations in schizophrenia.
Background
Brain morphometric abnormalities have been exten-
sively reported in schizophrenia for more than three
decades. Following the initial report of brain volume
reductions in schizophrenia by Johnstone et al. [1] in
their computerized tomographic (CT) study, there have
been an ever-increasing number of reports of brain
morphometric abnormalities in schizophrenia using
more powerful imaging modalities [2, 3]. These studies
have used various quantitative measurements such as
ventricular: brain ratio (VBR), whole brain volume,
lobar volumes, volumes generated by region-of-interest
(ROI)-based parcellation of cortical and subcortical
structures using manual or semi-automated methods,
as well as whole-brain voxel-based or surface-based
analyses [3]. The majority of whole-brain morphometric
studies have used Voxel-based morphometry (VBM)
implemented in the Statistical Parametric Mapping (SPM)
software (Wellcome Department of Imaging Neuroscience,
London; http://www.fil.ion.ucl.ac.uk/spm) or surface-based
analysis implemented using the FMRIB Software Library
(FSL) [4]. Voxel-based morphometric studies have reported
both large scale [5] as well as circumscribed volumetric re-
ductions in regions like superior temporal gyrus [6], amyg-
dala and cingulate [7] between patients with first episode
schizophrenia and healthy comparison subjects. Similarly,
surface-based studies using FreeSurfer in schizophrenia pa-
tients have also reported extensive volumetric abnormal-
ities [8] on the one hand, to more circumscribed changes
on the other [9].
The morphometric findings reported in schizophrenia
using the various methods described above are summa-
rized in reviews by Shenton et al. [10] (whole brain and
regional parcellation studies); Honea et al. [11] (voxel-
based morphometric studies); Steen et al. [12] (volu-
metric studies in first-episode psychosis); Navari and
Dazzan [13] (morphometric abnormalities in relation to
neuroleptic use) and Bora et al.[14] (a coordinate-based
meta-analysis to assess the effects of gender, chronicity,
negative symptoms and other clinical variables on re-
gional brain metrics). It is evident from these reviews
that whole brain volumetric reductions are consistently
reported in almost all the studies. However, replicability
of reported regional brain morphometric abnormalities
using whole-brain voxel-wise analyses has been far
from satisfactory [11]. This has led many researchers to
even question the validity of the reported brain mor-
phometric abnormalities in schizophrenia [15, 16]. The
factors contributing to inconsistency of brain morpho-
metric findings in schizophrenia include heterogeneity
of symptom characteristics [17]; variable duration of
illness (recent-onset vs. chronic) [18]; unequal gender
distribution [19] and handedness of study samples [20];
age of onset (typical onset vs. late-onset) [21], medication
status (drug-naïve or drug-free vs. medicated) [13] as
well as life-time substance abuse [22]. Factors pertain-
ing to Magnetic resonance imaging (MRI) acquisition
(strength of the magnet, acquisition protocols etc.) [23]
and analyses (hypothesis-free whole brain voxel-based
analyses vs. ROI-based analyses with or without a
priori hypotheses) also deserve attention while examin-
ing the issue of poor replicability of regional brain mor-
phometric findings in schizophrenia. It has been
pointed out that many of the above-mentioned con-
founding factors are not given adequate consideration
while undertaking group comparisons [10, 12]. Perhaps
the most serious methodological consideration in
whole-brain voxel-based morphometric analyses is the
reporting of results without specifying whether they are
corrected for multiple comparisons or not [24]. We
have recently reported the importance of controlling
for the socio-demographic and clinical confounding
factors affecting brain volumes as well as the use of
statistical significance thresholds corrected for multiple
comparisons in brain morphometric studies of schizo-
phrenia [25]. Another major issue that is often not
given its due consideration is the bias against publica-
tion of negative findings [16].
Therefore, as the primary objective of this study we
examined brain morphometry in a sample of patients
with predominant positive symptoms of schizophrenia
(paranoid and undifferentiated sub-types as well as
schizophreniform disorder) of recent onset (<5 years
duration) (and therefore either neuroleptic-naïve or
with limited neuroleptic exposure), in comparison to a
healthy control sample matched for age, handedness
(all right-handed) and gender distribution, using whole-
brain voxel-based and surface-based analyses as well as
John et al. Journal of Negative Results in BioMedicine    Page 2 of 15
ROI-based analyses using automated parcellation. By
including only patients with recent-onset schizophrenia
with limited neuroleptic exposure and by matching
socio-demographic variables during recruitment phase
as well as controlling for their influence on brain
morphometry by including them as co-variates during
statistical analyses, we expected to make reliable infer-
ences regarding morphometric abnormalities, if any,
that are hallmarks of the neurodevelopmental [26]
disease process of schizophrenia. In keeping with the
majority of previous reports, we expected that there
would be significant whole brain volumetric reduction
in patients with schizophrenia. However, in view of the
lack of evidence for consistently replicated regional
morphometric abnormalities from previous studies
after controlling for all the above confounding factors,
we assumed the null hypothesis that there would be no
significant regional differences in grey matter volume
in patients with schizophrenia in comparison to
matched healthy control subjects.
Results
The socio-demographic and clinical characteristics of
the study samples are given in Table 1. There were no
significant differences in age, gender-distribution and
level of education between schizophrenia and healthy
control samples.
There were no significant differences in age- and
intra-cranial volumetric (ICV) -adjusted total brain vol-
ume (TBV) between patients with schizophrenia (mean =
1080, S.E. = 3.242) when compared to healthy subjects
(mean = 1087, S.E. = 3.570) using analysis of covariance
(ANCOVA), with ICV, gender and age as co-variates
(F = 2.671; p < 0.106) (Fig. 1). No significant differences
in TBV were seen even on two-way ANOVA without
co-variates (F = 0.659, p < 0.419). As expected there was
a significant effect of gender on total brain volume in
both healthy and schizophrenia subjects, but upon cor-
rection for ICV-differences, the gender effect disap-
peared (Additional file 1: Table S3).
A trend-level difference in age- and ICV-adjusted
TBV was noted between healthy subjects, neuroleptic
naïve patients and medicated patients using ANCOVA
with age, gender and ICV as co-variates (F = 2.732;
p < 0.071). Post-hoc pair-wise comparisons revealed
that medicated patients with recent-onset schizophre-
nia (ROS) (n = 24) (mean = 1075, S.E. = 4.407) had sig-
nificantly lower age- and ICV-adjusted TBV when
compared to healthy comparison subjects (HCS) (n = 45)
(mean = 1087, S.E. = 3.550) (Mean difference: Healthy-
Medicated = 12.729, S.E. = 5.575; Bonferroni-adjusted
p < 0.025), while no significant differences in age- and
ICV-adjusted TBV emerged between neuroleptic-naïve pa-
tients with ROS (n = 21) (mean = 1086, S.E. = 4.837) and
HCS (n = 45). Medicated patients had significantly longer
duration of illness in comparison to neuroleptic-naïve
patients [Medicated patients: mean (in months) =30.21;
s.d. = 17.245; Neuroleptic-naïve patients: mean (in
months) = 17.81; s.d. = 17.113] (t = 2.145, p < 0.020).
Group-wise comparison of age-, ICV- and duration of
illness-adjusted TBV between medicated (mean = 1066,
S.E. = 4.505) and neuroleptic-naïve (1082, S.E. = 4.846)
patients with ROS using ANCOVA with age, gender,
ICV and duration of illness as covariates revealed
Table 1 Socio-demographic and clinical characteristics of the
study samples




group (n = 45)
Gender, n (%)
Male 35 (77.8) 32 (71.1)
Female 10 (22.2) 13 (28.9)















Positive 15.09 (5.29) 7–27
Negative 15.16 (4.82) 7–27
General 26.53 (5.96) 16–44
Total 56.78 (12.26) 39–
89
Age at onset of illness, years:
mean (s.d.) range
26.11 (8.35) 15–45















T-tests showed no significant differences (p ˂ 0.05) in age between patients
and controls. Among patients, no significant gender differences in age at
onset, duration of illness, or medication was found
aLife-time cumulative neuroleptic exposure expressed in risperidone equivalents
(mg) (Woods [56]; Taylor [57]; Kroken et al. [58])
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significantly lower TBV in medicated patients (F =
5.532, p < 0.024).
No significant regional volumetric differences emerged
between schizophrenia and healthy subjects using any of
the three morphometric approaches, namely, VBM (at false
discovery rate (FDR) p < 0.05), FreeSurfer (Monte-Carlo
(MC-Z) p < 0.05) and ROI-based analysis of FreeSurfer-
generated volumes (p < 0.0007, two-tailed). The ‘uncor-
rected’ (P < 0.001; k = 0 voxels) results generated by VBM
without including any co-variates in the design matrix are
presented in Fig. 2 and Table 2. The ‘uncorrected’ (P <
0.001; k = 0 voxels) results generated by VBM when TBV,
age and gender were entered as nuisance factors are pre-
sented in Fig. 3 and Table 3. As may be seen from the Ta-
bles 2 and 3, the results of VBM analyses with and without
the 3 co-variates are more or less similar, except that the
number of clusters identified at the statistical threshold of
p < 0.001 uncorrected were marginally lesser when the 3
co-variates were included in the design matrix. The
Fig 2 Statistical parametric t-map of gray matter volumes shown as reduced in schizophrenia subjects (N = 45) in comparison to healthy subjects
(N = 45) at a significance threshold of p < 0.001 uncorrected and an extent threshold of 0 voxels, when no co-variates were entered in the two
sample random effects analysis (RFX)
Fig. 1 Comparison of total brain volume (TBV) (in ml) between
patients with recent-onset schizophrenia (ROS) (N = 45; mean =
1072.74; s.d. = 117.81) and healthy control subjects (HCS) (N = 45;
1093.16; s.d. = 120.89); The central red line represents the mean, the pink
box represents the standard error of mean and the blue box, the
standard deviation
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uncorrected (P < 0.001) results using FreeSurfer Qdec
GUI with diagnosis (ROS vs. HCS) and gender as fixed
factors and TBV and age as co-variates are given in
Additional file 1: Figure S1 and Table S4. Group com-
parisons of regional volumes generated by FreeSurfer
using ANCOVA in Statistical Package for Social Sciences
(SPSS) revealed no brain regions that showed significant
volumetric changes at the Bonferroni-corrected statistical
threshold of p < 0.0007, nor even trend-level differences at
p < 0.05.
As detailed above, we found significant effects of medi-
cation on total brain volume. In order to examine medica-
tion effects on regional brain volumes, we carried out
exploratory VBM analyses between neuroleptic-naïve
patients with ROS and HCS (Additional file 1: Figure
S2; Table S5); medicated patients with ROS and HCS
(Additional file 1: Figure S3; Table S6) as well as medi-
cated patients with ROS and neuroleptic-naïve patients
with ROS (Additional file 1: Figures S4 and S6; Tables S7
and S8). None of the above contrasts revealed volumetric
differences at the FDR p < 0.05 statistical threshold. Never-
theless, trend-level regional volumetric reductions were
noted in both neuroleptic-naïve and medicated patients in
comparison to healthy control subjects (Additional file 1:
Figures S2 and S3; Tables S5 and S6). On the other hand,
VBM comparisons between neuroleptic-naïve (n = 21) vs.
medicated (n = 24) patients with age, gender, TBV and
duration of illness as co-variates revealed volumetric
increases in cerebellum (bilateral posterior declive and
right posterior pyramis) and right inferior parietal lobule
(Additional file 1: Figure S4; Table S7) as well as volumet-
ric decreases in right pre-central gyrus and right inferior
frontal gyrus in medicated patients (Additional file 1:
Figure S5; Table S8).
Discussion
We aimed at examining whole- and regional-brain
morphometric abnormalities in a sample of patients
with recent-onset schizophrenia using three commonly
used morphometric methods, controlling for the most
important socio-demographic and clinical confounding
factors that can potentially impact brain morphology in
schizophrenia. We found no significant whole- or regional-
brain volumetric differences at the appropriate statistical
significance thresholds in our sample of patients having
recent-onset schizophrenia with limited neuroleptic expos-
ure, in comparison to the healthy control sample matched
for age and gender distribution.
As mentioned in the Introduction, the major focus of
this study was to examine whether whole- or regional-
brain morphometric abnormalities are detectable in a
sample of patients with schizophrenia even after con-
trolling for possible socio-demographic and clinical
confounding factors that could impact brain volumes.
Table 2 Brain regions showing volumetric reductions in
schizophrenia subjects at a significance threshold of p < 0.001
uncorrected and an extent threshold of 0 voxels when no
co-variates were entered in the two sample random effects
analysis (RFX)







1 Left Limbic Lobe −20.37 −17.52 −7.19 4.10988
2 Left Limbic Lobe
Parahippocampal
Gyrus
−35.56 −11.33 −12.26 3.33252
3 Left Inferior Frontal
Gyrusa
−32.72 20.67 −7.83 3.77623
6 Left Posterior
Cingulateb
0.14 −44.61 9.51 3.60518
8 Right Limbic Lobe
Parahippocampal
Gyrus
21.34 −15.82 −11.72 3.57726
9 Right Limbic Lobe
Uncus
28.59 −6.77 −32.37 3.50207
10 Right Middle
Temporal Gyrusb




−32.88 −75.1 −23.66 3.4462
13 Left Middle Frontal
Gyrus
−26.49 5.75 43.56 3.37068
14 Left Middle
Occipital Gyrus




24.13 −39.06 −19.28 3.28409
16 Right Occipital
Lobe, Cuneus
1.3 −91.52 13.2 3.2631
17 Left Limbic Lobe
Parahippocampal
Gyrus
−18.81 1.55 −14.81 3.24654




−28.73 −65 −20.12 3.21802
20 Right Sub-lobar
Insula




−39.78 −66.55 −24.32 3.2137
22 Right Occipital
Lobe, Lingual Gyrus
4.24 −93.02 −0.41 3.21088
23 Left Temporal Lobe,
Sub-Gyral
−38.28 −2.67 −14.19 3.19289
24 Left Inferior
Occipital Gyrus
−27.58 −88.01 −7.23 3.14937
25 Left Temporal Lobe
Fusiform Gyrusb
−50.88 −45.92 −18.5 3.1054
a3 clusters significant at p < 0.001 uncorrected; cluster with higher
z-score listed
b2 clusters significant at p < 0.001 uncorrected; cluster with higher
z-score listed
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We have recently reported the importance of control-
ling for these confounding factors in brain morphomet-
ric studies of schizophrenia [25]. In the present study,
we attempted to control for the effect of these con-
founding factors at the subject recruitment as well as
data analysis stages. The effects of disease chronicity
and cumulative neuroleptic exposure on brain volumes
were minimized by including only patients with recent-
onset schizophrenia having a maximum duration of ill-
ness of 5 years.
Approximately half (n = 21; 46.67%) of the study sample
(N = 45) were neuroleptic-naïve and another 20% (n = 9)
were drug-free at the time of recruitment into the study.
The study samples were group-matched for age, gender
distribution and educational status. Moreover, age and
gender were entered as covariates in the between-group
volumetric comparisons. For the whole-brain volumetric
(TBV) comparisons, ICV was used as an additional covari-
ate (to examine the differences in whole brain volume
controlling for variability of intracranial volumes), while
for the whole-brain voxel-wise comparisons, TBV was
used as an additional covariate (to examine whether there
are regional brain morphometric abnormalities even after
controlling for whole brain volumetric differences).
Contrary to our a priori hypothesis, we found no
significant differences in TBV between our sample of pa-
tients with recent-onset schizophrenia in comparison to
matched healthy control subjects, when age, gender and
ICV were entered as co-variates. A large number of pre-
vious morphometric studies in schizophrenia (chronic/
recent-onset/medicated/ neuroleptic-naïve) [2, 12, 27],
including a previous study on neuroleptic-naïve patients
with recent-onset schizophrenia from our own group
[28] have reported significant/trend-level reductions of
total brain volume in patients when compared to healthy
control subjects. It is quite possible that this whole brain
volumetric reduction in schizophrenia might indicate the
influence of aberrant neurodevelopmental processes (e.g.,
aberrant glutamate signaling secondary to intra-uterine or
perinatal insults) on overall brain development [29] in
Fig. 3 Statistical parametric t-map of gray matter volumes shown as reduced in schizophrenia subjects (N = 45) in comparison to healthy subjects
(N = 45) at a significance threshold of p < 0.001 uncorrected and an extent threshold of 0 voxels, with total brain volume (TBV) age and gender entered
in the two sample random effects analysis (RFX) as co- variates
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keeping with the neurodevelopmental hypothesis of schizo-
phrenia [26]. While whole-brain volumetric reductions
may indeed be a hallmark of schizophrenia, the results of
our study indicate that in carefully chosen samples of
patients with recent-onset schizophrenia and limited
neuroleptic exposure, significant differences in total brain
volume need not necessarily be evident in comparison to
age- and gender-matched healthy control samples, espe-
cially when other possible clinical confounders are mini-
mized at the sample recruitment stage using appropriate
inclusion and exclusion criteria. Figure 1 depicts the sub-
stantial overlap of brain volumes between the schizophre-
nia and healthy samples, indicating that whole brain
volumes may not necessarily vary according to the pheno-
type (i.e., schizophrenia vs. healthy subjects); but perhaps
could be mediated by other factors discussed later.
In the present study, whole-brain morphometric ana-
lyses using both VBM and FreeSurfer-based methods did
not reveal significant regional volumetric differences be-
tween schizophrenia and healthy control samples. As noted
earlier, our schizophrenia sample comprised of patients
with recent-onset illness having had only minimal exposure
to neuroleptics. Moreover, the socio-demographic variables
(age and gender distribution) and total brain volume were
entered as nuisance co-variates and the statistical signifi-
cance threshold was set at FDR p < 0.05 for VBM8 and
Monte-Carlo Simulation p < 0.05 for FreeSurfer, corrected
for multiple comparisons. Trend-level volumetric reduc-
tions were noted at a statistical significance threshold of
p < 0.001 uncorrected (extent threshold k = 0 voxels) in
patients with schizophrenia; the findings being largely
comparable irrespective of whether the co-variates (age,
gender and TBV) were included in the design matrix or
not (Figs. 2 and 3; Tables 2 and 3). This may be due to the
fact that the samples were age- and gender-matched and
also because the TBV was not significantly different be-
tween the two samples. However the results of VBM and
FreeSurfer analyses did not show high concordance, per-
haps because, at the uncorrected statistical significance
threshold, the findings across two methods using different
registration algorithms may not be very reliable.
The brain regions that showed a trend towards volu-
metric reduction in schizophrenia (at p < 0.001 uncor-
rected) in the present study include bilateral frontal,
bilateral medial temporal, bilateral cerebellum, right an-
terior and posterior cingulate, right insula, right superior
temporal gyrus, right lentiform nucleus, left superior
parietal lobule and left middle and inferior occipital gyri.
Almost all these brain regions have been reported to
show volumetric reductions in previous morphometric
studies of schizophrenia. However, it must be mentioned
that virtually every brain region has been reported to
show volumetric reductions in schizophrenia in different
studies, even though, no specific brain region or a set of
Table 3 Brain regions showing volumetric reductions in
schizophrenia subjects at a significance threshold of p < 0.001
uncorrected and an extent threshold of 0 voxels, with total
brain volume (TBV), age and gender entered in the two sample
random effects analysis (RFX) as co-variates







1 Left Limbic Lobe,
Parahippocampal
Gyrusa
−20.38 −18.92 −7.32 3.95225
3 Left Inferior Frontal
Gyrusb
−34.13 19.15 −6.65 3.7467
6 Right Limbic Lobe
Parahippocampal
Gyrus




−32.85 −73.57 −24.87 3.46501
8 Left Middle Frontal
Gyrus
−26.49 5.75 43.56 3.45607
9 Left Limbic Lobe,
Posterior Cingulate
0.14 −44.61 9.51 3.44248
10 Right Limbic Lobe,
Uncus




22.72 −39.19 −17.97 3.38461
12 Right Middle
Temporal Gyrus
50.82 1.49 −31.21 3.3579
13 Left Middle
Occipital Gyrus
−36.02 −83.29 2.53 3.3346
14 Left Inferior
Occipital Gyrus




−28.71 −68.27 −21.59 3.25773
17 Right Cerebellum 1.71 −78.86 −15.33 3.22923
18 Left Limbic Lobe,
Parahippocampal
Gyrus
−18.81 1.55 −14.81 3.21702
19 Right Sub-lobar,
Insula




−39.78 −66.55 −24.32 3.17812
21 Left Inferior Frontal
Gyrus
−25.68 8.97 −18.28 3.11841
22 Right Superior
Frontal Gyrus




−21.71 −45.94 −19.36 3.10443
24 Right Limbic Lobe
Parahippocampal
Gyrus
33.85 −17.15 −12.99 3.10001
a2 clusters significant at p < 0.001 uncorrected; cluster with higher
z-score listed
b3 clusters significant at p < 0.001 uncorrected; cluster with higher
z-score listed
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brain regions have been shown to be reduced in volume
consistently across all or a majority of the previous stud-
ies. Given the various methodological issues related to
morphometric studies in schizophrenia, we are refrain-
ing from making attempts to discuss the neurobiological
significance of these trend-level regional brain morpho-
metric observations.
There have been many reports of regional brain mor-
phometric abnormalities in schizophrenia using Voxel-
based morphometry [11] and FreeSurfer analysis [8, 9].
Such reports have emanated from studies with sample
sizes ranging from 14 to 20 [5, 30, 31] to up to 173 [8]
patients with schizophrenia. However, since many of
these studies have not adequately controlled for the con-
founding factors discussed above and since many have
not used statistical significance thresholds corrected for
multiple comparisons, interpreting the results of such stud-
ies is challenging. Nevertheless, it is interesting to note that
many studies carried out on relatively smaller samples of
patients with recent-onset schizophrenia have reported sig-
nificant volumetric reductions at stringent statistical
thresholds (FDR or FWE-corrected) (e.g., [30, 31]). This in-
dicates that the findings of significant morphometric differ-
ences between patients with schizophrenia and healthy
control subjects may not be dependent on the sample sizes,
but more likely due to other factors such as molecular
genetic-, socio-demographic- and/or clinical variables that
vary across the samples studied. This issue would be fur-
ther handled in detail subsequently.
In the present study, regional cortical volumes gener-
ated using automated segmentation and parcellation by
FreeSurfer [32] did not show significant volumetric
differences between schizophrenia and healthy control
subjects. Previous ROI-based analyses using manual,
semi-automated and fully automated regional parcella-
tion schemes have reported morphometric abnormalities
in schizophrenia subjects [3, 10, 12]. Many of these stud-
ies are limited by small sample sizes (N = 12-22) [33, 34],
variable duration of illness and clinical heterogeneity
[18]. A systematic meta-review by Shepherd et al. [35] of
the structural brain alterations in schizophrenia showed
a large volume of conflicting low quality evidence and
limited high quality evidence supporting gray or white
matter changes in schizophrenia.
Therefore, the results of the present study refute our a
priori hypothesis that whole brain volumetric reduction
will be noted even in the early stages of schizophrenia
(duration of illness ≤5 years) and will be demonstrable
even after controlling for the socio-demographic and
clinical confounding factors that affect brain volumes at
the sample recruitment and analysis stages. On the con-
trary, the negative regional brain morphometric findings
of the study confirm our a priori hypothesis. Previous
reports of regional brain morphometric abnormalities in
schizophrenia show wide variability, perhaps due to the
confounding effects of the various socio-demographic
and clinical variables that affect brain morphology. Hav-
ing controlled for the above confounding variables at the
sample recruitment and data analyses stages; and having
used stringent statistical significance thresholds correct-
ing for multiple comparisons for between-group com-
parisons, there were no detectable statistically significant
regional brain morphometric abnormalities.
Effect of medication exposure on brain volumes
Medicated patients with recent-onset schizophrenia had
significantly lower total brain volume than healthy con-
trol subjects as well as neuroleptic-naïve patients. On
VBM analysis, both neuroleptic-naïve and medicated
patients showed a trend (p < 0.001 uncorrected; k = 0
voxels) towards lower regional volumes in comparison
to healthy subjects (Additional file 1: Figures S2 and S3
and Tables S5 and S6). However, medicated patients
showed a trend towards volumetric increases in cerebel-
lum (bilateral posterior declive and right posterior pyra-
mis) and right inferior parietal lobule (Additional file 1:
Figure S4; Table S7) as well as volumetric decreases in
right pre-central gyrus and right inferior frontal gyrus in
comparison to neuroleptic-naïve patients (Additional file
1: Figure S5; Table S8).
Medicated patients had significantly higher duration of
illness in comparison to neuroleptic-naïve patients. This
could be the reason why medicated patients showed sig-
nificantly lower total brain volume than healthy control
subjects as well as neuroleptic-naïve patients. However,
controlling for total brain volume, medicated patients
showed a trend towards predominantly increased regional
volumes in cerebellum and right inferior parietal lobule in
comparison to neuroleptic-naïve patients. The issue of
cortical and basal ganglia volumetric changes associated
with antipsychotics is a hotly debated topic with various
studies reporting decrease in cortical and subcortical
volumes (e.g., [36, 37] (review)); increase in volume of
basal ganglia structures (e.g., [38]), as well as conflicting
findings of differential effects of typical and atypical anti-
psychotics (e.g., [13] (review), [39–41]) on brain. Increased
brain volumes in medicated vs. neuroleptic-naïve patients
with schizophrenia have been previously reported [36, 42].
Many studies have also reported no significant changes as-
sociated with both typical as well as atypical antipsychotic
treatment (e.g., [43]). One must also keep in mind that the
methodological issues concerning brain morphometric
studies discussed in the Introduction are relevant for stud-
ies that have reported effects of medication on brain
volume, and may have contributed to the inconsistent re-
ports. Therefore, it is our opinion that there is no definite
evidence regarding effect of medications on brain volume
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in our sample, and the trend-level findings reported here
may at best be considered preliminary.
Strengths and limitations of the study
The strengths of the present study include homogeneity of
the patient sample with respect to clinical presentation,
recent onset (≤5 years duration) of illness, and limited
neuroleptic exposure. The diagnosis of schizophrenia was
made with great rigor by obtaining a consensus between
clinical diagnosis of an expert clinician and a research diag-
nosis generated by MINI-Plus interview. Moreover, diag-
nostic stability over 1–3 years was examined by reviewing
the follow-up notes; ten subjects were excluded from the
final sample following this exercise (vide Additional file 1:
Table S1). The healthy and schizophrenia samples did not
show significant differences in age, gender distribution and
educational status. The structural images were acquired
using a high resolution 3 Tesla scanner.
The results of morphometric analyses carried out
using the three most commonly employed methods
showed remarkable consistency in that all the three
methods failed to show significant regional brain mor-
phometric abnormalities in schizophrenia when com-
pared to healthy comparison subjects at the appropriate
significance thresholds. Confounding factors that are
relevant for both the groups such as ICV/TBV, age and
gender were entered during analysis as covariates. The
sample sizes were adequate for whole-brain voxel-wise
analyses using VBM and FreeSurfer. However, given the
large number of ROIs entered in automated parcellation-
based analysis (n = 68, covering both hemispheres), recruit-
ing an adequate number of patients with recent-onset
schizophrenia for group comparisons using ANCOVA was
not feasible in a single-center study of this nature. Even
though majority of our sample of patients with schizophre-
nia had no or limited previous exposure to neuroleptics
(67%) (Table 1), it would have been ideal if all recruited pa-
tients were drug-naïve. Moreover, it needs to be pointed
out that we have not considered many other factors
such as socio-economic and nutritional status, IQ,
stress levels, body weight etc. that may affect brain
morphology and that could also have a potential, albeit
indirect relation with the risk of developing schizophre-
nia. Another limitation of the present study is the ab-
sence of diffusion tensor imaging (DTI), which could
have thrown light on white matter structural integrity
changes in the same sample. Nevertheless, we found
that there were no significant differences in total white
matter volume between patients and control subjects
as examined using ANCOVA controlling for age, gen-
der and ICV (F = 0.11, p < 0.752).
It may be argued that the absence of significant regional
morphometric abnormalities in the present study could be
due to a Type II error owing to ‘inadequate’ sample sizes.
As mentioned earlier, the studies that have reported sig-
nificant morphometric abnormalities in schizophrenia
using VBM and FreeSurfer analyses have had sample sizes
ranging from 14 to 173 patients. On carefully reviewing
these studies, there is no indication to suggest that studies
with larger sample sizes have consistently reported more
extensive or more specific regional morphometric abnor-
malities or that studies with smaller sample sizes consist-
ently failed to find significant differences (due to Type II
error). Indeed, studies with sample sizes as low as 14–20
patients with schizophrenia (neuroleptic/chronic) have re-
ported extensive volumetric reductions in multiple brain
regions [44]. In this context, the recently reported findings
of the largest international multi-site mega-analysis com-
prising of 784 patients with schizophrenia and 986
healthy control subjects [45] are quite illuminating.
VBM comparisons between these two large samples for
the Control > Schizophrenia contrast yielded significant
(at FDR p < 0.05) differences in gray matter volumes in
regions that covered most of the brain in a single clus-
ter. Thus the robust finding to emerge from the above
mega-analysis using voxel-wise statistics was the
whole-brain volumetric reduction in the schizophrenia
sample. The global maxima of the above diffuse volu-
metric reduction was located in the MNI space in be-
tween the right insula and putamen and not in the left
superior temporal gyrus or hippocampus or the pre-
frontal cortical regions that have been hitherto the
most consistently reported regions showing brain mor-
phometric alterations in schizophrenia [11, 46, 47].
More intriguingly, global maxima of the above mega-
analysis was not found to show volumetric reductions
in a recent meta-analysis of over 18,000 subjects [42].
In the above meta-analysis, medicated patients (n =
8327) were found to have diffuse volumetric reductions
spanning almost the entire brain, along with reduced
total brain, total gray and total white matter volumes.
Neuroleptic-naïve patients, on the other hand, were
shown only to have volumetric reductions in the bilat-
eral hippocampus, thalamus and caudate, apart from
the whole brain measures (total, gray and white). More-
over, thalamus and caudate were not shown to have
volumetric reductions in the medicated group. This
cannot be explained as the effect of neuroleptic expos-
ure on increasing thalamic and caudate volumes, in
which case, with a sample size of 8327, one would expect
a significant increase in volume of these structures in the
medicated group to be picked up. It must be noted that
the ‘fail-safe number’ of the above meta-analysis on
neuroleptic-naïve patients was quite small, while Egger’s
regression test indicated publication bias for many of the
brain regions reported to show volumetric reductions in
medicated patients. Perhaps the most important finding of
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this meta-analysis is the finding of a robust association be-
tween gray matter reduction and longer duration of illness
as well as higher dose of antipsychotics. This might ex-
plain the consistent whole brain volumetric reductions re-
ported in the literature so far, since the majority of such
studies were carried out in patients with longer duration
of illness and having had exposure to neuroleptics over a
longer period of time. The fact that the present study was
carried out in a moderate-sized (n = 45) sample of patients
with recent-onset schizophrenia with limited neuroleptic
exposure might be one of the reasons why we did not find
significant total brain volumetric reductions in our schizo-
phrenia sample.
The present study demonstrates how a given sample
of patients having recent onset schizophrenia with lim-
ited neuroleptic exposure may not show significant
whole- or regional-brain morphometric alterations in
comparison to a healthy control sample matched for
age, gender distribution and education. However, this find-
ing in no way suggests that a different sample of patients
with recent-onset schizophrenia will not show significant
volumetric differences with another healthy comparison
group. Such inconsistency of findings across different
samples of patients with recent-onset schizophrenia
would indicate that the reported brain morphometric
abnormalities in schizophrenia cannot directly be
linked to the schizophrenia phenotype, but may be
understood as epiphenomena that could putatively be
linked to molecular genetic epistatic and epigenetic in-
teractions as well as other socio-demographic and clin-
ical confounding factors such as duration of illness and
medication status. Moreover, given the inconsistencies
of brain morphometric findings from the mega- and
meta-analyses discussed above, it is amply clear that
the solution to resolve the puzzle of inconsistent mor-
phometric findings in schizophrenia is not increasing
sample sizes of structural neuroimaging studies in
schizophrenia. Previous studies discussed above that
have reported morphometric reductions at a stringent
statistical threshold (FDR- or FWE-corrected) despite
small sample sizes (e.g., [30, 31]) would lend further
support to this conclusion. Therefore, it is important
that researchers in the field should consider giving up
their ‘wishful thinking’ that consistent morphometric
findings in schizophrenia would emerge simply by in-
creasing the sample sizes. Indeed, a more logical strat-
egy would be to examine the sources of the variability
of morphometric findings across samples, most import-
ant of which are the molecular genetic factors. These
factors might include genetic and epigenetic factors, in-
cluding the individual and additive effects of the mul-
tiple genes responsible for schizophrenia diathesis on
brain development, as recently reported from our
laboratory [48, 49].
Conclusions
The present study showed that in a carefully selected
sample of patients with schizophrenia having recent-
onset illness (≤5 years from onset) with limited/no
exposure to neuroleptics, there may not be demonstrable
whole- or regional-brain morphometric alterations in
comparison to age-, gender- and education-matched
healthy comparison subjects at the appropriate signifi-
cance thresholds. However, our finding in no way
suggests that a different sample of patients with recent-
onset schizophrenia will not show significant volumetric
differences with another healthy comparison group. This
implies that demonstrable whole- or regional-brain mor-
phometric abnormalities are not hallmarks of the schizo-
phrenia phenotype, but could be epiphenomena related
to molecular genetic epistatic and epigenetic interactions
as well as other socio-demographic and clinical con-
founding factors such as duration of illness and medica-
tion status. Therefore, the results of the present study
indicate that the relationship between brain volumetric
alterations and the schizophrenia phenotype cannot be
conceptualized using a simplistic (cause-effect) frame-
work. On the contrary, in silico models that simulate
gene-gene (epistatic) and gene-environment (epigenetic)
interactions affecting brain morphology might provide
us with a more comprehensive understanding regarding
complexities underlying the brain morphometric alter-
ations associated with schizophrenia [50].
Methods
Ethics statement
The study was carried out at the National Institute of Men-
tal Health and Neurosciences (NIMHANS), Bangalore,
India, with due approval from the National Institute of
Mental Health and Neurosciences Human Ethics Commit-
tee, thus conforming to the ethical standards laid down in
the 1964 Declaration of Helsinki. Written informed con-
sent was obtained after detailed explanation of the study
protocol, from all the subjects (and their accompanying
relatives in the case of individuals with schizophrenia, as
required by the NIMHANS Ethics Committee) prior to en-
rollment into the study.
Study samples
The study samples comprised of forty five patients with
ROS, recruited from those who attended the outpatient
services of NIMHANS by purposive sampling and forty
five HCS recruited by word of mouth from hospital staff
and attendants of hospitalized patients. A total of 109 sub-
jects (schizophrenia subjects = 58; healthy comparison sub-
jects = 51) were recruited into the study from which the
above samples were derived, with 19 subjects having to be
dropped for various reasons (Additional file 1: Table S1).
Only right-handed subjects (as determined by modified
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Annett’s inventory [51], aged between 17 and 50 years, and
with an Mini-Mental Status Examination (MMSE) [52]
score of ≥23 were recruited into the study. The presence of
any unstable medical/neurological condition was ruled out
in both groups of subjects using an unstructured clinical
interview, detailed physical examination and baseline la-
boratory investigations. The diagnosis of schizophrenia or
schizophreniform disorder was arrived at using criteria
from the Diagnostic and Statistical Manual for Mental
Disorders-Fourth Edition (DSM-IV) [53] based on the con-
sensus of an experienced research psychiatrist (J.P.J.) who
conducted a semi-structured interview and a trained re-
search assistant who used the Mini International Neuro-
psychiatric Interview (MINI) Plus [54]. Moreover, prior to
arriving at the final sample of patients with schizophrenia
for morphometric analyses, we reviewed the case files of all
subjects to examine for diagnostic stability, with the dur-
ation of follow-up ranging from 1 to 3 years. As given in
Additional file 1: Table S1, ten subjects were removed from
the schizophrenia/ schizophreniform disorder sample after
this exercise. Only those patients who did not meet criteria
for any other Axis I disorder, including substance depend-
ence (other than nicotine) as per MINI-Plus, with an age
of first onset of psychotic symptoms at or after 17 years of
age and a duration of illness less than or equal to 5 years
were recruited into the study. All patients had predomin-
ant positive symptoms and had diagnoses of paranoid (n =
30), undifferentiated (n = 8) or schizophreniform (n = 7)
subtypes. The patients with schizophreniform disorder in-
cluded in the morphometric analysis comprised of only
those who were re-diagnosed as schizophrenia during
follow-up and who retained a diagnosis of schizophrenia
even after 1–3 years, as inferred from follow-up data ob-
tained from case files. The baseline severity of schizophre-
nia psychopathology was evaluated using the Positive and
Negative Syndrome Scale (PANSS) [55] by two trained
raters who had established good inter-rater reliability. The
history of exposure to antipsychotics was ascertained by
interviewing the patient and relative/s, and corroborated
from available medical records. Thirty of the forty five
patients were not on neuroleptics, of which 21 were drug
naïve at the time of recruitment into the study. The
remaining patients were on antipsychotics, the cumulative
doses of which were converted to ‘risperidone equivalents’
[56–58] (Table 1). The details of lifetime exposure to neu-
roleptics of patients who were exposed to neuroleptics are
given in Additional file 1: Table S2. The healthy compari-
son subjects were ascertained to be free from Axis I or II
psychiatric disorders using the MINI-Plus. Current use/
abuse of psychotropic drugs as well as history of psychi-
atric illness in first-degree relatives in the healthy compari-
son subjects were ruled out by an unstructured clinical
interview. The socio-demographic and clinical characteris-
tics of the samples are given in Table 1.
Structural MRI
Image acquisition
Magnetic resonance imaging (MRI) structural images were
acquired on a Philips Achieva 3.0 T scanner using a
SENSE-8 head coil. Head movements were minimized by
applying a band over the forehead during the scanning
procedure. A high-resolution T1-weighted MRI volume
data set of the whole brain with a resolution of 1 × 1 ×
1 mm3 was acquired using an MPRAGE (Magnetization
Prepared Rapid Gradient Echo) sequence: Repetition time
(TR) = 8.2 ms, echo time (TE) = 3.8 ms, flip angle = 8°,
sense factor: 3.5.
Image preprocessing and analyses
All scans were inspected visually for any gross structural
abnormality by an expert neuroradiologist. The MR images
were first converted from DICOM format to NIFTI format
using dcm2nii software (http://www.mccauslandcenter.
sc.edu/mricro/mricron/dcm2nii.html).
Whole-brain morphometric analyses permit hypothesis-
free testing of volumetric differences between schizophre-
nia and healthy comparison subjects [6, 59]. Such
approaches require transforming brains from different
participants into a common reference frame using either
volume-based registration or surface-based registration.
We performed whole-brain morphometric comparisons
between schizophrenia and healthy control samples using
the most commonly used software utilizing volume-based
registration, viz., VBM8 and surface-based registration,
viz., FreeSurfer, version 5.1.
Voxel-Based Morphometry (VBM)
Voxel-based morphometry was performed using Christian
Gaser’s VBM8 toolbox (http://dbm.neuro.uni-jena.de/
vbm8/) running on Statistical Parametric Mapping 8 soft-
ware (SPM8) (http://www.fil.ion.ucl.ac.uk/spm). Prior to
VBM analysis, the images were visually inspected for arte-
facts or other structural anomalies and one image each
from the healthy and the schizophrenia samples were
omitted (refer Additional file 1: Table S1). Briefly, the
image pre-processing steps using VBM8 toolbox gener-
ated normalized, segmented, modulated, and smoothed
(using a Gaussian filter of kernel size 8 mm Full Width
Half Maximum (FWHM)) gray matter (GM) images with
a voxel size of 1 mm3, which were used for further statis-
tical analysis. Spatial normalization was achieved by using
the standard Montreal Neurological Institute (MNI) 152
template. Analysis of modulated data tests for regional dif-
ferences in absolute amount (volume) of GM. We did not
use any explicit or threshold masks in our whole-brain
voxel-wise analysis. The total GM, white matter (WM)
and ICV were generated from the VBM analysis. The TBV
were calculated as sum of GM and WM volumes.
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Free Surfer-based whole brain analysis
Cortical reconstruction and volumetric segmentation was
performed with the Freesurfer image analysis suite, freely
available online (http://surfer.nmr.mgh.harvard.edu/), the
technical details of which have been described previously
[32]. Briefly, this method uses both intensity and continuity
information from the entire three dimensional MR volumes
in segmentation and deformation procedures to produce
representations of cortical thickness, calculated as the clos-
est distance from the gray/white boundary to the gray/CSF
boundary at each vertex on the tessellated surface. After a
careful visual inspection for any gross anatomical abnor-
malities, all the scans were run as a batch on FreeSurfer
v.5.1. Once the entire subject pool finished running, we
made sure the reconstruction was successful by checking
for Talairach registration. The adequacy of skull stripping,
generation of white and pial surfaces, and segmentations
were evaluated by the checking the images using TKME-
DIT. Freesurfer completed the processing of the images
without any need for manual interventions. The details of
integration of surface- and volume-based representations
are given in Makris et al. [60] and Desikan et al. [61].
ROI-based analyses using FreeSurfer-generated regional
volumes
The FreeSurfer software package provides a method for
complete automated parcellation of the cerebral cortex
and subcortical structures [61]. The software segments the
cortex and parcellates the surface into standardized
regions of interest (ROIs). It allows for automated anatom-
ical parcellation of cortex into gyral regions and subse-
quently surface parcellation is extended to GM volume,
yielding parcellation of GM tissue sheet and regions of
interest (ROIs). ROI based volumetric data were extracted
and group comparisons performed using the SPSS version
16 for Windows.
Statistical analyses
Statistical analyses of demographic and clinical charac-
teristics were performed using two-tailed Student’s
t-test or Chi-square tests, as appropriate. Assumptions
for normality were tested for all volumetric and demo-
graphic variables using Kolmogorov-Smirnov’s test of
normality in the SPSS. Total brain volume (TBV) gen-
erated by VBM8 was compared between schizophrenia
and healthy control subjects using General Linear
Model (GLM) ANCOVA with ICV, age and gender as
co-variates. Age, gender and intracranial volume have
been reported to influence whole brain and regional
brain volumes (19).
We chose to use TBV generated by VBM for our ana-
lyses, given the unreliability of calculating ICV from T1
scans by FreeSurfer. This issue has been highlighted by
the authors of FreeSurfer, who suggest using other image
analyses modalities for ICV correction, while computing
brain volumes (http://www.freesurfer.net/fswiki/eTIV).
Voxel-wise whole-brain morphometric analysis using VBM
Whole-brain voxel-wise comparisons of gray matter be-
tween schizophrenia and healthy subjects was carried out
in VBM8 using General Linear Model (GLM) Analysis of
Co-variance (ANCOVA) with the ‘nuisance factors’ listed
earlier as co-variates. Since SPM uses a mass univariate
approach, correction for multiple comparisons was ap-
plied by employing FDR estimations with the level of sig-
nificance set a priori at p < 0.05, while addressing the
primary objective of the study, which was to examine
group differences in brain volumes between patients with
schizophrenia and matched healthy control subjects.
Surface-based whole brain morphometric analysis using
FreeSurfer
The effects of diagnosis on cortical volume were evaluated
for both hemispheres using GLM at each vertex, with
gender as fixed factor and TBV and age as covariates using
Freesurfer. The statistical significance level of the vertex-
wise analysis in Freesurfer was set at p < 0.05 after
Monte-Carlo (MC-Z) simulation for multiple comparisons.
ROI-based analysis of FreeSurfer-generated regional volumes
using SPSS
Group comparison between schizophrenia and healthy
subjects of 34 regional brain volumes on either hemisphere
generated by automated parcellation using Freesurfer, was
carried out using SPSS. Assumptions for normality were
tested for all volumetric and demographic variables using
Kolmogorov-Smirnov’s test of normality. Of the 34 vol-
umes on either hemisphere, the following variables were
not normally distributed: Left hemisphere: entorhinal, post-
central and rostral middle frontal cortices; Right hemi-
sphere: entorhinal, medial orbito frontal, lateral orbito
frontal, pars orbitalis and temporal pole cortices. These
variables were winsorised [62] and log10x transformed to
achieve normal distribution for parametric tests. For the
variables that did not achieve normal distribution despite
the above method (left: post-central; right: lateral orbito
frontal and pars orbitalis), Mann-Whitney U test was used
for group comparisons. All the other variables were com-
pared between the schizophrenia and healthy subjects by
General Linear Model (GLM) Analysis of Co-variance
(ANCOVA) with diagnosis and gender as fixed factors and
age and TBV as covariates.
Additional file
Additional file 1: Table S1. Total number of subjects recruited into the
study, reasons for dropping subjects, and final n of each sample. Table S2.
Details of lifetime exposure to neuroleptics and duration of neuroleptic use
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(n = 24). Table S3. Comparison of total brain volume between males and
females in the recent-onset schizophrenia (ROS) (N= 45) and the healthy
control subject (HCS) (N = 45) samples. Between-gender analysis of
covariance (ANCOVA) in both samples with age as covariate revealed
significant gender differences in both samples when intracranial volume (ICV)
was not used as an additional covariate; whereas there were no significant
gender differences in total brain volume when ICV was used as an
additional covariate. Table S4. Brain regions showing volumetric
reductions in schizophrenia subjects in comparison to healthy subjects at a
significance threshold of p < 0.001 uncorrected, on vertex-wise analysis using
Freesurfer, with gender entered as a fixed factor and age, and total brain
volume as nuisance factors. Table S5. Brain regions showing volumetric
reductions in drug naïve schizophrenia subjects (N = 21) in comparison to
healthy control subjects (N = 45) at a significance threshold of p < 0.001
uncorrected and an extent threshold of 0 voxels when total brain volume
(TBV), age and gender were entered in the two sample random effects
analysis (RFX) as co-variates. Table S6. Brain regions showing volumetric
reductions in medicated schizophrenia subjects (N = 24) in comparison to
healthy control subjects (N = 45) at a significance threshold of p < 0.001
uncorrected and an extent threshold of 0 voxels when total brain volume
(TBV), age and gender were entered in the two sample random effects
analysis (RFX) as co-variates. Table S7. Brain regions showing volumetric
reductions in neuroleptic-naïve schizophrenia subjects (N = 21) in
comparison to medicated schizophrenia subjects (N = 24) at a significance
threshold of p < 0.001 uncorrected and an extent threshold of 0 voxels
when total brain volume (TBV), age, gender and duration of illness were
entered in the two sample random effects analysis (RFX) as co-variates.
Table S8. Brain regions showing volumetric increases in neuroleptic-naïve
schizophrenia subjects (N= 21) in comparison to medicated schizophrenia
subjects (N = 24) at a significance threshold of p < 0.001 uncorrected and an
extent threshold of 0 voxels when total brain volume (TBV), age, gender and
duration of illness were entered in the two sample random effects analysis
(RFX) as co-variates. Figure S1. Freesurfer-generated difference (t) map of
brain volumes depicting grey matter volumes shown as reduced in
schizophrenia subjects (N = 45) in comparison to healthy subjects
(N = 45) at p < 0.001 uncorrected with gender entered as fixed factor
and total brain volume and age as nuisance factors. Figure S2.
Statistical parametric t-map of gray matter volumes shown as reduced
in drug naïve schizophrenia subjects (N = 21) in comparison to healthy
control subjects (N = 45) at a significance threshold of p < 0.001 uncorrected
and an extent threshold of 0 voxels with total brain volume (TBV), age and
gender were entered in the two sample random effects analysis (RFX) as
co-variates. Display according to neurological convention (image left is
participant’s left). Figure S3. Statistical parametric t-map of gray matter
volumes shown as reduced in medicated schizophrenia subjects (N = 24) in
comparison to healthy control subjects (N = 45) at a significance threshold
of p < 0.001 uncorrected and an extent threshold of 0 voxels when total
brain volume (TBV), age and gender were entered in the two sample
random effects analysis (RFX) as co-variates. Display according to neurological
convention (image left is participant’s left). Figure S4. Statistical parametric
t-map of gray matter volumes shown as reduced in neuroleptic-naïve
schizophrenia subjects (N = 21) in comparison to medicated schizophrenia
subjects (N = 24) at a significance threshold of p < 0.001 uncorrected and an
extent threshold of 0 voxels when total brain volume (TBV), age, gender and
duration of illness were entered in the two sample random effects analysis
(RFX) as co-variates. Display according to neurological convention (image
left is participant’s left). Figure S5. Statistical parametric t-map of gray matter
volumes shown as increased in neuroleptic-naïve schizophrenia subjects
(N = 21) in comparison to medicated schizophrenia subjects (N = 24) at a
significance threshold of p < 0.001 uncorrected and an extent threshold of 0
voxels when total brain volume (TBV), age, gender and duration of illness
were entered in the two sample random effects analysis (RFX) as co-variates.
Display according to neurological convention (image left is participant’s left).
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